{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
M016
(2024)
Source URL:
First approved in 2023
Source:
Joint health by XIAN CHIANG COMPANY LIMITED
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Quit Smoking Patch by Guangzhou Hanhai Trading Co., Ltd
(2023)
Source URL:
First approved in 2023
Source:
Quit Smoking Patch by Guangzhou Hanhai Trading Co., Ltd
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
BLA125795
(2023)
Source URL:
First approved in 2023
Source:
BLA125795
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
BLA125771
(2023)
Source URL:
First approved in 2023
Source:
BLA125771
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
ANDA075357
(2023)
Source URL:
First approved in 2023
Source:
ANDA075357
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Digestive Patch by Guangzhou Hanhai Trading Co., Ltd
(2023)
Source URL:
First approved in 2023
Source:
Digestive Patch by Guangzhou Hanhai Trading Co., Ltd
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NADA141562
(2023)
Source URL:
First approved in 2023
Source:
NADA141562
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
GOHIBIC by InflaRx GmbH
(2023)
Source URL:
First approved in 2023
Source:
GOHIBIC by InflaRx GmbH
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
M020
(2023)
Source URL:
First approved in 2023
Source:
M020
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT03169660: Phase 4 Interventional Completed Exudative Age-related Macular Degeneration
(2015)
Source URL:
First approved in 2023
Source:
DR.K CELL REPAIR GENIC AMPOULE by Noblesse Korea Co., Ltd.
Source URL:
Class:
PROTEIN